| payload |
{"created_at":"2026-04-07T03:18:43.308 {"created_at":"2026-04-07T03:18:43.308311+00:00","dedupe_key":"signal_enriched:discovery_sec_filing_delta:ec007e35dcb85562","evidence_event_ids":["evt_01c06587881b"],"signal_type":"discovery_sec_filing_delta","source":"discovery_sec_filings","value":{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1001233/0001947007-26-000008.txt","as_of":"2026-04-07T03:18:43.308311+00:00","canonical_url":"https://www.sec.gov/Archives/edgar/data/1001233/0001947007-26-000008.txt","company":"SANGAMO THERAPEUTICS, INC","enrichment":{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1001233/0001947007-26-000008.txt","article_chars":3618,"article_truncated":false,"blocked_reason":null,"candidate_id":"sc_bfe0f6b1c5e57a87","canonical_host":"sec.gov","canonical_is_aggregator":false,"canonical_url":"https://www.sec.gov/Archives/edgar/data/1001233/0001947007-26-000008.txt","content_type":"text/plain","enriched_at":"2026-04-07T09:49:10.420652+00:00","extraction_method":"heuristic","fetched_description":"","fetched_title":"","final_url":"https://www.sec.gov/Archives/edgar/data/1001233/0001947007-26-000008.txt","html_truncated":false,"paywall_likely":false,"publisher_domain":"sec.gov","publisher_resolution":"canonical_url","requested_url":"https://www.sec.gov/Archives/edgar/data/1001233/0001947007-26-000008.txt","source_event_id":"evt_01c06587881b","source_quality":"high","status_code":200,"version":"signal_enrichment_v2"},"form_type":"144","fp":"d7a4e9175419ed7a","kind":"sec_filing","published_at":"20260406","publisher_domain":"sec.gov","signal_understanding":{"analysis_basis":"article","claim_confidence":0.9,"dates_mentioned":["2026-04-06"],"entities":[{"asset_class":"equity","name":"Sangamo Therapeutics, Inc.","relevance":"issuer","symbol":"SGMO","type":"company"}],"event_type":"listing","information_gaps":["Details on the number of shares to be sold are not provided."],"key_facts":["Form 144 filed on April 6, 2026.","Reporting owner: Nathalie Dubois-Stringfellow, an officer of the company.","The filing indicates potential sales of common stock."],"numeric_claims":[],"primary_claim":"Sangamo Therapeutics, Inc. filed Form 144 on April 6, 2026.","relevance_score":0.7,"sentiment":"neutral","source_quality":"high","summary":"Sangamo Therapeutics, Inc. filed Form 144 on April 6, 2026, indicating potential sales of common stock by an officer.","topics":["SEC filing","stock sales","Sangamo Therapeutics"]},"source":"sec_edgar","source_domain":"sec.gov","summary":"Form 144 \u00b7 SANGAMO THERAPEUTICS, INC \u00b7 Filed 20260406","ticker":"SGMO","tickers":["SGMO"],"title":"SGMO filed 144","url":"https://www.sec.gov/Archives/edgar/data/1001233/0001947007-26-000008.txt"}}... |